Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference

BEDMINSTER, N.J., March 24, 2011 /PRNewswire/ — Omthera
Pharmaceuticals, Inc., a privately-held emerging specialty
pharmaceuticals company, announced today that Jerry Wisler,
President and Chief Executive Officer, will present at the BIO
Windhover/Pharmaceutical Strategic Outlook 2011 Conference at the
Grand Hyatt in New York, on March 31, 2011 at 2:30pm ET.

About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera
Pharmaceuticals, Inc. is a privately-held, emerging specialty
pharmaceuticals company focusing its efforts on the clinical
development of new therapies for dyslipidemia. Led by a team
of experts with exceptional experience in developing new therapies
for lipid disorders, Omthera is dedicated to developing innovative
therapies for the millions of patients who have elevated
triglyceride levels and increased risk of cardiovascular
disease. The Company recently initiated a pivotal Phase III
clinical trial for its lead product candidate, Epanova™, an
Omega-3 fatty acid compound in development as a
triglyceride-lowering adjunct therapy to diet in patients with very
high triglycerides (greater than or equal to 500 mg/dL). Future
planned clinical trials for Epanova include patients with high
triglycerides (greater than or equal to 200 mg/dL and less than or
equal to 500 mg/dL) currently on statin therapy. Omthera
holds worldwide rights to Epanova under a license from Chrysalis
Pharma AG, a privately held Swiss Company that is the owner of the
product.